Thermo Fisher Scientific reported robust second-quarter 2025 results, surpassing Wall Street estimates for both profit and revenue. The company achieved revenues of $10.85 billion, marking a 3% year-over-year increase with organic growth at 2%, driven by steady demand for its tools and services used in developing therapies.
Adjusted operating income for the quarter reached $2.38 billion, growing 1% year-over-year, resulting in an adjusted operating margin of 21.9%. This performance was achieved despite macroeconomic headwinds, largely offset by strong productivity improvements from the company's Practical Process Improvement (PPI) Business System.
Following these strong results, Thermo Fisher raised its full-year 2025 adjusted EPS outlook to a range of $22.22 to $22.84. This updated guidance reflects the Q2 beat and an additional $0.10 of adjusted EPS expected in the second half of the year from further cost actions, signaling confidence in continued operational excellence and financial performance.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.